Lars Fruergaard Jørgensen began his career at Novo Nordisk as an economist in the health care, economy, and planning ...

While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining dose in short supply — the lowest dose of Wegovy — is now listed as available, CNN reported. “We’re ...

Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

Novo Nordisk is working on a new obesity drug that could help patients ... Semaglutide, the GLP-1 drug that Novo sells under ...

Novo Nordisk’s dominance in the obesity and diabetes markets, already bolstered by the success of Wegovy and Ozempic, could be further strengthened if CagriSema lives up to expectations. Obesity ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...